Occuity

06/11/2025

Our Republic Europe crowdfunding round is now live. Secure your priority access, log in now and invest.
👉 Invest here: https://zurl.co/LFmHF

Not registered yet? Do not worry, you can still take part. Simply visit the page below to learn more about our mission, our technology and our plans for growth, and you will be able to invest from as little as £30.

At Occuity, we are working to make Oculomics a practical reality, using the eye as a window into the health of the body. It is an exciting time for the business and we are delighted to now open this next phase of our journey.

Thank you for your early support. It genuinely means a great deal to our team.

Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 minutes to learn more: https://zurl.co/BumkP

05/11/2025

What if a simple, pain-free scan of the eye could help detect and monitor diseases like glaucoma, myopia, diabetes and even Alzheimer’s?

At Occuity, we are building the technology that could make this possible.

Our CEO and Co-Founder, Dan Daly, explains in our new campaign video five reasons why now is the perfect time to invest in Occuity:

👁️ We are using the eye as a window into the health of the body, unlocking earlier, easier and more accessible diagnostics
🔬 Our patented optical platform is already proven and protected, with 15 patents filed
🧑🔬 We have a highly experienced team with award-winning engineers and scientists
📈 We are already generating revenue through our first commercial device and a global distribution network
🚀 We have a clear roadmap, with each device strengthening our platform on the journey toward non-invasive glucose monitoring

This is not a concept. This is a British MedTech company with commercial traction and global ambition.

🎥 Watch the video and learn more about the investment opportunity:
https://zurl.co/hzP73

Invest from as little as £30.

Risk Warning:
Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 minutes to learn more: https://zurl.co/nfcej

31/10/2025

⏳ Why Priority Access matters: It allows you to maintain your shareholding, increase your position, or join the round before allocations fill. Once public, allocation is not guaranteed. Pre-register now: https://zurl.co/pHHrO

Don't invest unless you're prepared to lose all the money you invest.
This is a high-risk investment and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more: https://zurl.co/8pm6Q

30/10/2025

🚀 Priority Access is now open for our investment round on Republic. Existing investors & those who pre-registered can secure their allocation before the public launch.

Get Priority Access now: https://zurl.co/WkhXm

Don't invest unless you're prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more: https://zurl.co/W4jc3

When investing, capital is at risk. Improving the lives of millions of people with non-invasive disease detection through a scan of the eye

27/10/2025

We’re pleased to announce that pre-registration is now open for the next phase of Occuity’s investment round, hosted on Republic (formerly Seedrs).

🚀 From our CE-marked PM1 Pachymeter for glaucoma screening to our forthcoming AX1 Axiometer™ for myopia management, Occuity is redefining non-contact optical diagnostics and building the foundations of a future where major diseases can be detected through the eye.

🔗 Pre-register now: https://zurl.co/nqEJX

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more. https://zurl.co/tsz6W

08/10/2025

Occuity joins UK Prime Minister on Trade Mission to India

We’re incredibly proud to share that our CEO and Co-founder, Dr Dan Daly, was invited to join UK Prime Minister Sir Keir Starmer as part of the current official UK Government Trade Delegation to India.

This is a huge moment for Occuity - recognition that we’re among the UK’s most promising MedTech innovators. Alongside some of Britain’s leading companies, Dan will be discussing how we're using the eye as a window to the health of the body to detect diseases such as diabetes, myopia and Alzheimer’s through a simple eye scan.

India represents an exciting opportunity to extend the reach of our technology to where it’s needed most — supporting screening and monitoring in clinics, pharmacies and even rural communities.

We’re honoured to represent UK innovation on this world stage and look forward to forging partnerships that will help make healthcare more accessible across the globe.

👉 Read more: https://zurl.co/WhABu

Occuity CEO, Dr. Dan Daly joins UK Prime Minister Sir Keir Starmer on the official UK Government Trade Delegation to India

28/09/2025

Our Crowdcube campaign closes in 12 hours https://zurl.co/Wp0M3

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment & you are unlikely to be protected if something goes wrong. Take 2 mins to learn more. https://zurl.co/2NXpQ

27/09/2025

Tick, Tick, Tick - Time is almost up. Our Crowdcube campaign closes tomorrow – giving you just one final day to take action, become a shareholder, and join us on our mission.
Occuity is pioneering handheld, non-contact devices that use the eye as a window to health. From managing childhood myopia to tackling chronic conditions like diabetes and Alzheimer’s, our technology has the potential to democratise healthcare worldwide.

This is your last chance to back:

* A proven team who have already delivered a world-first medical device
* A patented platform with both short-term traction and long-term growth potential
* A mission that could improve the lives of hundreds of millions of people

Don’t miss out on being part of this journey.

👉 Invest now before the round closes - https://zurl.co/pn6K6)

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more. https://zurl.co/2NXpQ

26/09/2025

⏰ Our Crowdcube round closes in just 2 days!

Don’t miss out – if you believe in our mission to make healthcare more accessible and improve the lives of millions, now is the time to back us. We’re developing handheld, non-contact devices that can transform how conditions like myopia and diabetes are detected and managed.

Check out the campaign and join us before it’s too late: https://zurl.co/Wp0M3

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more. https://zurl.co/2NXpQ

25/09/2025

Don't forget to join us for our Webinar! Not signed up? There's still time...

https://zurl.co/O4FeN

hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more. https://zurl.co/2NXpQ

22/09/2025

Webinar: 👓 Don’t be myopic – Join us to really ‘see’ the opportunity! - 10am | Thursday 25 Sept

Thinking about joining our crowdfunding campaign?

This is your chance to see how Occuity is planning to transform healthcare – through a simple scan of the eye. Join us to learn more about our ambitious plans, our strategy to deliver on our mission, and how we’re tackling some of the world’s biggest health challenges.

In this live session, Occuity CEO, Dan Daly, will cover:

- The groundbreaking technology behind Occuity’s handheld devices
- Why the AX1 Axiometer™ is set to be a game-changer in myopia management
- How our diabetes products could replace painful fingerstick tests with a simple, pain-free scan of the eye
- Why diabetes screening is even more important
- Our strategy and thinking around exit plans for investors
- A live Q&A session to answer your questions directly

With a minimum investment of just £30, this is your opportunity to hear from our CEO, ask questions, and understand why Occuity offers both short-term traction and long-term growth potential.

Sign up today here: https://zurl.co/jD2CQ

We look forward to welcoming you to the webinar.



Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more. https://zurl.co/2NXpQ

08/09/2025

Occuity's ultimate vision is a BIG one - a future where a simple eye scan at your doctors, local optician or pharmacy could detect early signs of diabetes or Alzheimer’s — before the damage they cause appear as symptoms.

That’s the future we’re working towards with our grant-funded screening devices.

By targeting systemic diseases through the eye — a field known as Oculomics — we ar eworking to bring early detection into accessible, everyday healthcare settings. We believe prevention is better than cure.

These devices are the long-term future of Occuity, built on the same core optical technology as the PM1, AX1, and Indigo.

We’re raising now to accelerate this vision.

✅ Pre-register today for early access 👉 https://zurl.co/GxucN

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more. https://zurl.co/2NXpQ